• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Charles & Colvard Ltd (Amendment)

    5/9/23 9:23:06 PM ET
    $CTHR
    Consumer Specialties
    Consumer Discretionary
    Get the next $CTHR alert in real time by email
    SC 13D/A 1 schedule13da1.htm AMENDMENT NO. 1 TO SCHEDULE 13D

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    Schedule 13D/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)

     

     

    Charles & Colvard LTD

    (Name of Issuer)

     

     

    Common Stock

    (Title of Class of Securities)

     

     

    159765106

    (CUSIP Number)

     

     

    Ryan Reiffert

    Law Offices of Ryan Reiffert, PLLC

    8118 Datapoint Dr.

    San Antonio, TX 78229

    (210) 817-4388

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

     

    May 5, 2023

    (Date of Event which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d–1(e), 240.13d–1(f) or 240.13d–1(g), check the following box. □

     

     

     

     

     

     



     

     

     

     

    CUSIP No.  159765106

    1

    NAME OF REPORTING PERSON

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

    Carlos Daniel Valadez

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) □

    (b) □

     

         

    3

    SEC USE ONLY

    4

    SOURCE OF FUNDS (See Instructions)

    PF

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

    □     

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    State of Texas, U.S.A.

     

    7

    SOLE VOTING POWER

    1,789,133

     

    8

    SHARED VOTING POWER

    0

     

    9

    SOLE DISPOSITIVE POWER

    1,789,133

     

    10

    SHARED DISPOSITIVE POWER

    0

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,789,133

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    □     

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    5.86%(1)

    14

    TYPE OF REPORTING PERSON

    IN

    _________________________________

     

    (1)Based upon 30,523,705 shares of the Issuer’s common stock issued and outstanding as of March 31, 2023, as reported on the Issuer’s Form 10-Q for the quarter ended March 31, 2023. 

     

     

     

     

     

     

     

     

     

     

    SCHEDULE 13D/A

     

    This Amendment No. 1 to Schedule 13D (this “Amendment”) amends and supplements the statements on the Schedule 13D filed by Mr. Carlos Daniel Valadez (“Mr. Valadez”) with the Securities and Exchange Commission (the “Commission”) on April 10, 2023.

     

    The Schedule 13D is amended and supplemented by adding the information contained herein. Only those items amended are reported herein. Items having no amendments or changes are not reported herein.

     

     

    Item 3.

    Source and Amount of Funds

    Item 3 is hereby amended and restated in its entirety as follows:

    All shares of Common Stock reported in the previous Schedule 13D were purchased by the Reporting Person between March 16, 2023 and April 6, 2023 and were purchased with the Reporting Person’s personal funds. The total purchase price for the Common Stock previously reported was approximately $1,668,579.

    Between April 6, 2023 and May 5, 2023, the Reporting Person purchased 215,002 additional shares of Common Stock with the Reporting Person’s personal funds. The total purchase price for the Common Stock purchased between April 6, 2023 and May 5, 2023 was approximately $204,252.

    The total aggregate purchase price for all Common Stock purchases between March 16, 2023 and May 2, 2023 was approximately $1,872,831. All such purchases were made using the Reporting Person’s personal funds.

      

    Item 5.

    Interest in Securities of the Issuer

     

    Item 5 of the Schedule 13D is amended and restated in its entirety as follows:

     

     

    (a)

    As of May 5, 2023, Mr. Valadez may be deemed to beneficially own 1,789,133 shares of Common Stock of the Issuer, which represents approximately 5.86% of the outstanding Common Stock of the Issuer. This percentage calculation is based on 30,523,705 shares outstanding, as reported on the Issuer’s Form 10-Q for the quarter ended March 31, 2023.

     

    (b)

    Mr. Valadez has sole voting or dispositive power with regard to 1,789,133 shares of Common Stock of the Issuer, which represents approximately 5.86% of the outstanding Common Stock of the Issuer. This percentage calculation is based on 30,523,705 shares outstanding, as reported on the Issuer’s Form 10-Q for the quarter ended March 31, 2023.

     

    (c)

    On March 16, 2023, Mr. Valadez purchased an aggregate of 377,139 shares of Common Stock in 42 open market broker transactions at prices ranging from $0.89 to $1.10 per share, with a weighted average of $0.96 per share.

    On March 31, 2023, Mr. Valadez purchased an aggregate of 36,668 shares of Common Stock in 10 open market broker transactions at prices ranging from $0.90 to $0.95 per share, with a weighted average of $0.94 per share.

    On April 3, 2023, Mr. Valadez purchased an aggregate of 591,096 shares of Common Stock in 97 open market broker transactions at prices ranging from $0.91 to $1.30 per share, with a weighted average of $1.07 per share.

    On April 4, 2023, Mr. Valadez purchased an aggregate of 2,000 shares of Common Stock in 2 open market broker transactions at prices ranging from $0.98 to $0.99 per share, with a weighted average of $0.99 per share.

    On April 5, 2023, Mr. Valadez purchased an aggregate of 106,635 shares of Common Stock in 23 open market broker transactions at prices ranging from $0.98 to $1.02 per share, with a weighted average of $1.01 per share.

    On April 6, 2023, Mr. Valadez purchased an aggregate of 460,593 shares of Common Stock in 86 open market broker transactions at prices ranging from $0.99 to $1.24, with a weighted average of $1.17 per share.

    On May 5, 2023, Mr. Valadez purchased an aggregate of 215,002 shares of Common Stock in open market broker transactions, with a weighted average of $0.95 per share.

    Mr. Valadez’s average price per share for the aggregate of all the above transactions is $1.05 per share.

     

     

     

    (d)

    No person other than the Reporting Person is known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, the Common Stock.

     

    (e)

    Not applicable

     

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: May 9, 2023

     

     

     

     

     

     

     

     

    /s/ Carlos Daniel Valadez

    Carlos Daniel Valadez

     

     

    Get the next $CTHR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CTHR

    DatePrice TargetRatingAnalyst
    9/3/2021$3.50 → $3.75Buy
    Roth Capital
    More analyst ratings

    $CTHR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Charles & Colvard, Ltd. Announces Delisting from Nasdaq

      RESEARCH TRIANGLE PARK, N.C., April 22, 2025 /PRNewswire/ -- Charles & Colvard, Ltd. ("Charles & Colvard" or the "Company"), announced that the Company received a staff determination letter from the Nasdaq Stock Market, LLC ("Nasdaq"), informing the Company that Nasdaq determined to suspend trading and delist the Company's common stock (the "Common Stock") from Nasdaq because the Company is out of compliance with Listing Rule 5250(c)(1) for failure to timely file its Forms 10-Q for the quarters ended September 30 and December 31, 2024, unless the Company appeals this determination. The Company does not intend to request a hearing to appeal this determination. This decision was based on a car

      4/22/25 4:45:00 PM ET
      $CTHR
      Consumer Specialties
      Consumer Discretionary
    • Charles & Colvard, Ltd. Receives Expected Nasdaq Notice Regarding Delayed Form 10-Q

      RESEARCH TRIANGLE PARK, N.C., March 3, 2025 /PRNewswire/ -- Charles & Colvard, Ltd. ("Charles & Colvard" or the "Company") (NASDAQ:CTHR) today announced that on February 25, 2025, it received an expected notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") stating that the Company continues to not be in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule"), as a result of not having timely filed its Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2024. Nasdaq previously accepted the Company's plan to regain compliance with the Listing Rule and granted the Company until April 14, 2025 to file its Annual Report on For

      3/3/25 4:45:00 PM ET
      $CTHR
      Consumer Specialties
      Consumer Discretionary
    • Charles & Colvard, Ltd. Receives Interim Award in Wolfspeed Arbitration

      RESEARCH TRIANGLE PARK, N.C., Dec. 11, 2024 /PRNewswire/ -- Charles & Colvard, Ltd. ("Charles & Colvard" or the "Company") (NASDAQ:CTHR) today announced that on December 5, 2024, it received an interim award in its confidential arbitration with Wolfspeed, Inc.  Importantly, the award rejected Wolfspeed's claims to expectation damages of approximately $22.8 million, limiting the Company's damages to just $3.3 million representing approximately $1.3 million for inventory previously purchased and approximately $2.0 million of consigned inventory in the Company's possession, that will now be recorded on the Company's balance sheet as of June 30, 2024 - along with interest, arbitration and limite

      12/11/24 4:10:00 PM ET
      $CTHR
      Consumer Specialties
      Consumer Discretionary

    $CTHR
    Leadership Updates

    Live Leadership Updates

    See more
    • Milestone Scientific Announces CEO Transition, with Chairman Neal Goldman Serving as Interim CEO

      ROSELAND, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that its Chief Executive Officer Arjan Haverhals will retire from his role as an officer of the company on December 31, 2024. Upon his retirement, Mr. Haverhals will continue to serve as a director on the Board and will provide consulting services to ensure continuity and support through the leadership transition. Mr. Haverhals' retirement, following a distinguished career of over 30 years in the medical device and pharmaceutical industries, reflects his desire to spend more ti

      11/14/24 4:00:00 PM ET
      $CTHR
      $MLSS
      Consumer Specialties
      Consumer Discretionary
      Industrial Specialties
      Health Care
    • Charles & Colvard Joins Russell Microcap® Index

      RESEARCH TRIANGLE PARK, N.C., June 28, 2021 /PRNewswire/ -- Charles & Colvard, Ltd. (NASDAQ:CTHR) (the "Company"), a globally recognized fine jewelry company specializing in lab created moissanite and lab grown diamonds, announced today the Company's addition to the Russell Microcap® Index, effective after the US market opens on June 28, 2021, as a part of the Russell indexes annual reconstitution. Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines

      6/28/21 9:16:00 AM ET
      $CTHR
      Consumer Specialties
      Consumer Discretionary

    $CTHR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Roth Capital reiterated coverage on Charles & Colvard with a new price target

      Roth Capital reiterated coverage of Charles & Colvard with a rating of Buy and set a new price target of $3.75 from $3.50 previously

      9/3/21 8:46:46 AM ET
      $CTHR
      Consumer Specialties
      Consumer Discretionary

    $CTHR
    Financials

    Live finance-specific insights

    See more
    • CHARLES & COLVARD REPORTS THIRD QUARTER FISCAL YEAR 2024 FINANCIAL RESULTS

      Conference Call with Accompanying Slide Presentation Scheduled Today at 4:30 PM ET RESEARCH TRIANGLE PARK, N.C., May 2, 2024 /PRNewswire/ -- Charles & Colvard, Ltd. (NASDAQ:CTHR) (the "Company"), a globally recognized fine jewelry company that specializes in moissanite and lab grown diamonds, reported financial results for the third quarter ended March 31, 2024 ("Third Quarter Fiscal 2024").  Management Commentary  "We remain committed to growth despite a challenging third quarter. We believe our strategic initiatives, continued investments in innovative technology, and dedica

      5/2/24 4:07:00 PM ET
      $CTHR
      Consumer Specialties
      Consumer Discretionary
    • CHARLES & COLVARD TO HOST THIRD QUARTER FISCAL YEAR 2024 INVESTOR CONFERENCE CALL ON MAY 2, 2024 AT 4:30 PM ET

      RESEARCH TRIANGLE PARK, N.C., April 23, 2024 /PRNewswire/ -- Charles & Colvard, Ltd. (NASDAQ:CTHR) (the "Company"), a globally recognized fine jewelry company that specializes in moissanite and lab grown diamonds, will host an investor conference call and webcast presentation to discuss its financial results for the third quarter ended March 31, 2024 ("Third Quarter Fiscal Year 2024") at 4:30 p.m. ET on Thursday, May 2, 2024. The Company will release its financial results after market close on the same day. Third Quarter Fiscal Year 2024 Conference Call DetailsDate and Time: T

      4/23/24 4:08:00 PM ET
      $CTHR
      Consumer Specialties
      Consumer Discretionary
    • CHARLES & COLVARD REPORTS SECOND QUARTER FISCAL YEAR 2024 FINANCIAL RESULTS

      Conference Call with Accompanying Slide Presentation Scheduled Today at 4:30 PM ET RESEARCH TRIANGLE PARK, N.C., Feb. 13, 2024 /PRNewswire/ -- Charles & Colvard, Ltd. (NASDAQ:CTHR) (the "Company"), a globally recognized fine jewelry company that specializes in moissanite and lab grown diamonds, reported financial results for the second quarter ended December 31, 2023 ("Second Quarter Fiscal 2024").  Management Commentary  "We acknowledge the recent industry shift has presented us with numerous challenges and has significantly impacted our earnings. However, we do not believe t

      2/13/24 4:07:00 PM ET
      $CTHR
      Consumer Specialties
      Consumer Discretionary

    $CTHR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • O'Connell Don bought $5,550 worth of shares (15,000 units at $0.37) (SEC Form 4)

      4 - CHARLES & COLVARD LTD (0001015155) (Issuer)

      3/7/24 4:15:57 PM ET
      $CTHR
      Consumer Specialties
      Consumer Discretionary
    • Sykes Ollin B bought $7,028 worth of shares (19,000 units at $0.37) (SEC Form 4)

      4 - CHARLES & COLVARD LTD (0001015155) (Issuer)

      3/5/24 6:21:11 PM ET
      $CTHR
      Consumer Specialties
      Consumer Discretionary
    • O'Connell Don bought $4,806 worth of shares (13,350 units at $0.36), increasing direct ownership by 3% to 464,464 units (SEC Form 4)

      4 - CHARLES & COLVARD LTD (0001015155) (Issuer)

      3/5/24 9:15:15 AM ET
      $CTHR
      Consumer Specialties
      Consumer Discretionary

    $CTHR
    SEC Filings

    See more
    • SEC Form NT 10-Q filed by Charles & Colvard Ltd

      NT 10-Q - CHARLES & COLVARD LTD (0001015155) (Filer)

      5/16/25 5:06:09 PM ET
      $CTHR
      Consumer Specialties
      Consumer Discretionary
    • Charles & Colvard Ltd filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - CHARLES & COLVARD LTD (0001015155) (Filer)

      4/22/25 5:02:42 PM ET
      $CTHR
      Consumer Specialties
      Consumer Discretionary
    • SEC Form 10-K filed by Charles & Colvard Ltd

      10-K - CHARLES & COLVARD LTD (0001015155) (Filer)

      4/3/25 4:45:54 PM ET
      $CTHR
      Consumer Specialties
      Consumer Discretionary

    $CTHR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Charles & Colvard Ltd (Amendment)

      SC 13D/A - CHARLES & COLVARD LTD (0001015155) (Subject)

      2/26/24 7:00:57 PM ET
      $CTHR
      Consumer Specialties
      Consumer Discretionary
    • SEC Form SC 13G/A filed by Charles & Colvard Ltd (Amendment)

      SC 13G/A - CHARLES & COLVARD LTD (0001015155) (Subject)

      2/14/24 9:00:30 AM ET
      $CTHR
      Consumer Specialties
      Consumer Discretionary
    • SEC Form SC 13D/A filed by Charles & Colvard Ltd (Amendment)

      SC 13D/A - CHARLES & COLVARD LTD (0001015155) (Subject)

      11/20/23 4:15:12 PM ET
      $CTHR
      Consumer Specialties
      Consumer Discretionary

    $CTHR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • O'Connell Don bought $5,550 worth of shares (15,000 units at $0.37) (SEC Form 4)

      4 - CHARLES & COLVARD LTD (0001015155) (Issuer)

      3/7/24 4:15:57 PM ET
      $CTHR
      Consumer Specialties
      Consumer Discretionary
    • Sykes Ollin B bought $7,028 worth of shares (19,000 units at $0.37) (SEC Form 4)

      4 - CHARLES & COLVARD LTD (0001015155) (Issuer)

      3/5/24 6:21:11 PM ET
      $CTHR
      Consumer Specialties
      Consumer Discretionary
    • O'Connell Don bought $4,806 worth of shares (13,350 units at $0.36), increasing direct ownership by 3% to 464,464 units (SEC Form 4)

      4 - CHARLES & COLVARD LTD (0001015155) (Issuer)

      3/5/24 9:15:15 AM ET
      $CTHR
      Consumer Specialties
      Consumer Discretionary